Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude de recherche chez les enfants nés petits et qui sont restés petits. Le traitement est Somapacitan une fois par semaine par rapport à Norditropin® une fois par jour

5 octobre 2026 mis à jour par: Novo Nordisk A/S

Un essai de recherche de dose évaluant l'effet et l'innocuité d'un traitement une fois par semaine au somapacitan par rapport à une prise quotidienne de Norditropin® chez les enfants de petite taille nés petits pour l'âge gestationnel sans rattrapage de croissance à l'âge de 2 ans ou plus

The study compares 2 medicines used for the treatment of children who are born small and who stayed small: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe).

Participants will either get somapacitan or Norditropin® - which treatment is decided by chance. Both participants and the study doctor will know which treatment the participants get. The study will last for 5 years. Participants will take either an injection once every week or once every day.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

62

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Algiers, Algérie, 16000
        • CHU Bab El Oued Pediatrics Dept
      • Algiers, Algérie, 16000
        • Endo and Diab Dept El Oued
      • Constantine, Algérie, 25000
        • endocrino-diabetology department, Hospital IBN BADIS.
    • Alberta
      • Edmonton, Alberta, Canada, T6G 2B7
        • Stollery Children's Hospital
      • Copenhagen Ø, Danemark, 2100
        • Rigshospitalet Klinik for Vækst og Reproduktion Afsnit 5064
      • Esplugues Llobregat(Barcelona), Espagne, 08950
        • Hospital Sant Joan de Déu
      • Santiago de Compostela, Espagne, 15706
        • Hospital Clínico de Santiago de Compostela
      • Tallinn, Estonie, 13419
        • Tallinn Children's Hospital
      • Tartu, Estonie, 50406
        • Tartu University Hospital Children's Clinic
      • Angers, France, 49100
        • Centre Hospitalier Universitaire D'Angers-2
      • Le Kremlin-Bicêtre, France, 94270
        • AP-HP-HOPITAL DE BICETRE_Service d'Endocrinologie pédiatrique
      • Marseille, France, 13005
        • Assistance Publique Hopitaux de Marseille-Hopital de La Timone-2
      • Marseille Cédex 05, France, 13385
        • Hopital de La Timone
      • Paris, France, 75015
        • Ap-Hp-Hopital Necker
      • Paris, France, 75015
        • Hôpital Necker
      • Toulouse, France, 31059
        • HOPITAL DES ENFANTS-HOPITAL PAULE DE VIGUIER - Pharmacie
      • Budapest, Hongrie, 1023
        • Észak-Közép-budai Centrum, Szent János Kórház és Szakrendelő
      • Szeged, Hongrie, 6720
        • Szegedi Tudományegyetem Gyermekgyógyászati Klinika
    • Kerala
      • Kochi, Kerala, Inde, 682041
        • Amrita Institute Of Medical Sciences & Research Centre
    • Maharashtra
      • Pune, Maharashtra, Inde, 411001
        • Jehangir Clinical Development Centre
    • New Delhi
      • New Dehli, New Delhi, Inde, 110029
        • All India Institute of Medical Sciences
      • Dublin, Irlande, D12 N512
        • CHI Crumlin Dept of Endocrinology
      • Haifa, Israël, 31096
        • Rambam MC - Department of Pediatrics A
      • Kfar Saba, Israël, 44281
        • Meir MC - Department of Paediatrics
      • Petah Tikva, Israël, 49202
        • Schneider MC - Endrocrinology and Diabetes
      • Florence, Italie, 50139
        • IRCCS Meyer Firenze
      • Genova, Italie, 16147
        • Ospedale Pediatrico Gaslini
      • Milan, Italie, 20122
        • Ospedale Maggiore Policlinico UO Endocrinologia Diabetolgia
      • Roma, Italie, 00165
        • Ospedale Pediatrico Bambino Gesu
      • Fukuoka, Japon, 830-0011
        • Kurume University Hospital, Pediatrics
      • Fukuoka-shi, Fukuoka, Japon, 813-0017
        • Fukuoka Children's Hospital_Endocrinology and Metabolism
      • Fukuoka-shi, Fukuoka, Japon, 813-0017
        • Fukuoka Children's Hospital
      • Fukuyama-shi, Hiroshima, Japon, 721-8511
        • Fukuyama City Hospital_Department of Pediatrics
      • Kobe-shi, Hyogo, Japon, 650-0047
        • Hyogo Prefectual Kobe Children's Hospital Dept. Metab & endo
      • Kobe-shi, Hyogo, Japon, 650-0047
        • Hyogo Prefectual Kobe Children's Hospital_Metab & endo
      • Kyoto, Japon, 602-8566
        • Univ.HP, Kyoto Pref Univ of Medicine, Dept. of Pediatrics
      • Nara-shi, Nara, Japon, 630-8581
        • Nara Prefecture General Medical Center_ Nara-shi, Nara
      • Nara-shi, Nara, Japon, 630-8581
        • Nara Prefecture General Medical Center_Pediatric
      • Niigata-shi, Niigata, Japon, 951 8520
        • Niigata University Medical & Dental Hospital_Pediatrics
      • Osaka, Japon, 534-0021
        • Osaka City General Hospital, Pediatric Endocrinology and Me
      • Osaka, Japon, 594-1101
        • Osaka Women's and Children's Hospital
      • Saitama-shi, Saitama, Japon, 330-8777
        • Saitama Children's Medical Center, Endocrinorogy&Metabolism
      • Tokyo, Japon, 157 8535
        • National Center for Child Health and Dev, Endo and Metabo
      • Tokyo, Japon, 113-8519
        • Institute of Science Tokyo Hospital
      • Tokyo, Japon, 113-8519
        • Institute of Science Tokyo Hospital_Pediatrics
      • Tokyo, Japon, 157 8535
        • National Center for Child Health and Development_Endo and Metabo
      • Tokyo, Japon, 160-8582
        • Keio University Hospital_Pediatrics
      • Graz, L'Autriche, 8036
        • Med. Univ. Graz -Klinische Abteilung f. Allgemeine Pädiatrie
      • Salzburg, L'Autriche, A 5020
        • LKH Salzburg- Univ. Klinik f. Kinder- und Jugendheilkunde
      • Sankt Pölten, L'Autriche, 3100
        • LKH St. Poelten, Kinder-und Jugendheilkunde
      • Vöcklabruck, L'Autriche, 4840
        • Salzkammergut-Klinikum Vöcklabruck
    • Upper Austria
      • Linz, Upper Austria, L'Autriche, 4020
        • Kepler Universitätsklinikum GmbH - Med Campus IV (vorm.LFKK)
      • Riga, Lettonie, 1004
        • Children's Clinical University Hospital
      • Bergen, Norvège, 5021
        • Haukeland Universitetssykehus, Barneklinikken
      • Szczecin, Pologne, 71-252
        • SPSK nr 1 im Prof. T Sokolowskiego
      • Warsaw, Pologne, 04-730
        • Instytut ''Pomnik - Centrum Zdrowia Dziecka''
      • Hull, Royaume-Uni, HU3 2JZ
        • Hull Royal Infirmary
      • Liverpool, Royaume-Uni, L12 2AP
        • Alder Hey Children's Hospital
      • London, Royaume-Uni, E1 1BB
        • Royal London Hospital_London
      • Manchester, Royaume-Uni, M13 9WL
        • Royal Manchester Children's Hospital
      • Izhevsk, Russie, 426009
        • Republic Children's Hospital of Ministry of Health of Udmurt
      • Moscow, Russie, 119435
        • Setchenov First Moscow State Medical University
      • Moscow, Russie, 125373
        • RMAPE
      • Novosibirsk, Russie, 630048
        • Children's clinical city hospital #1
      • Rostov-on-Don, Russie, 344013
        • FSBEI of Higher Education "Rostov State Medical University"
      • Saint Petersburg, Russie, 191144
        • SPSBHI City Children out-patient clinic #44
      • Samara, Russie, 443079
        • Samara Regional Children Clinical Hospital n.a. N.N. Ivanova
      • Tomsk, Russie, 634050
        • Siberian State Medical University
      • Belgrade, Serbie, 11000
        • University Children's Hospital Tirsova
      • Belgrade, Serbie, 11070
        • Institute for Mother and Child Health Care of Serbia
      • Kragujevac, Serbie, 34000
        • University Clinical Centre Kragujevac
      • Niš, Serbie, 18 000
        • Clinical Center in Nis
      • Novi Sad, Serbie, 21000
        • Institute for Health Care of Children and Adolescents
      • Bern, Suisse, 3010
        • Med. Kinder- und Poliklinik
      • Zurich, Suisse, 8032
        • Kinderspital Endokrinologie, Zürich
      • Bangkok, Thaïlande, 10330
        • King Chulalongkorn Memorial hospital-Ped-Endocrinology
      • Bangkok, Thaïlande, 10330
        • King Chulalongkorn Memorial hospital_Ped-Endocrinology
      • Bangkok, Thaïlande, 10400
        • Phramongkutklao Hospital_Ped-Endo_Pediatrics
      • Dnipro, Ukraine, 49100
        • Dnipropetrovsk Regional Children's Clinical Hospital - Endocrinology department
      • Kharkiv, Ukraine, 61093
        • Kharkiv Regional Children's Clinical Hospital - Endocrinological department
      • Kyiv, Ukraine, 04114
        • Komisarenko Institute of Endocrinology and Metabolism of NAMSU - Department of paediatric endocrine pathology
    • Alabama
      • Birmingham, Alabama, États-Unis, 35233
        • Univ of AL at Birmingham_BRM
    • California
      • Orange, California, États-Unis, 92868
        • Children's Hosp Of Orange
    • Idaho
      • Boise, Idaho, États-Unis, 83712
        • St. Luke's Children's Endo
    • Minnesota
      • Minneapolis, Minnesota, États-Unis, 55454
        • Univ of Minnesota M.C.H.
      • Saint Paul, Minnesota, États-Unis, 55102
        • Children's Minnesota
    • New Jersey
      • Morristown, New Jersey, États-Unis, 07962
        • Goryeb Children's Hospital
      • New Brunswick, New Jersey, États-Unis, 08901
        • Rutgers-Rwjms
    • New York
      • Garden City, New York, États-Unis, 11530
        • NYU Langone Hospital-LI
      • Mineola, New York, États-Unis, 11501
        • NYU Langone Hospital-LI
      • New York, New York, États-Unis, 10029
        • Icahn Sch of Med-Mt Sinai Hosp
    • Ohio
      • Cincinnati, Ohio, États-Unis, 45229
        • CCHMC_Cinc
    • Oklahoma
      • Oklahoma City, Oklahoma, États-Unis, 73104
        • Univ Oklahoma Sci Ctr OK City
    • Texas
      • Fort Worth, Texas, États-Unis, 76104
        • Cook Children's Hospital-Hematology-Oncology
    • Washington
      • Tacoma, Washington, États-Unis, 98405
        • MultiCare Inst for Res & Innov

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

2 ans à 11 ans (Enfant)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Pre-pubertal children, boys:

    1. age between 2.5 and 11.0 years at screening.
    2. testes volume below 4 ml.
  • Pre-pubertal children, girls:

    1. age between 2.5 and 10.0 years at screening.
    2. Tanner stage 1 for breast development (no palpable glandular breast tissue).
  • Born small for gestational age (birth length and/or weight below -2 standard deviation scores) (according to national standards).

  • Impaired height defined as at least 2.5 standard deviations below the mean height for chronological age and gender at screening according to the standards of Centers for Disease Control and Prevention at screening.

  • Impaired height velocity defined as annualized height velocity below the 50th percentile for chronological age and gender according to the standards of Prader calculated over a time span of minimum 6 months and maximum 18 months prior to screening.

  • No prior exposure to growth hormone therapy or Insulin-like Growth Factor-I (IGF-I) treatment.

Exclusion Criteria:

  • Any known or suspected clinically significant abnormality likely to affect growth or the ability to evaluate growth with standing height measurements.
  • Children with hormonal deficiencies including suspected or confirmed growth hormone deficiency according to local practise.
  • Current inflammatory diseases requiring systemic corticosteroid treatment for longer than 2 consecutive weeks within the last 3 months prior to screening.
  • Children requiring inhaled glucocorticoid therapy at a dose of greater than 400 μg/day of inhaled budesonide or equivalents for longer than 4 consecutive weeks within the last 12 months prior to screening.
  • Concomitant administration of other treatments that may have an effect on growth, e.g but not limited to methylphenidate for treatment of attention deficit hyperactivity disorder.
  • Diagnosis of attention deficit hyperactivity disorder.
  • Prior history or presence of malignancy including intracranial tumours.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Somapacitan 0.24 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

Expérimental: Somapacitan 0.20 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

Expérimental: Somapacitan 0.16 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

Comparateur actif: Norditropin® 0.035 mg/kg/day

Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Norditropin® injected under the skin once a day.

Comparateur actif: Norditropin® 0.067 mg/kg/day

Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Norditropin® injected under the skin once a day.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Height Velocity
Délai: Baseline (week 0); week 26

Height velocity (HV) was derived from height measurements taken at baseline (week 0) and week 26 visit as: HV = (height at 26 weeks visit - height at baseline)/(time from baseline to 26 weeks visit in years). The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in Ratio of Bone Age Versus Chronological Age
Délai: Baseline (week 0); week 52

Change in ratio of bone age (years) versus chronological age (years) from baseline (week 0) to week 52 is presented. X-rays of left hand and wrist for bone age assessment according to the Greulich and Pyle atlas were taken. X-ray images were sent to a central imaging laboratory for evaluation. Chronological Age (years) was calculated as: (Date minus Date of Birth) divided by 365.25. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 52 or last trial contact, whichever came first.

Baseline (week 0); week 52
Change in Height Standard Deviation Score (HSDS)
Délai: Baseline (week 0); week 26

Change in HSDS from baseline (week 0) to week 26 is presented. HSDS was derived using Centre for Disease Control and Prevention (CDC) standards. HSDS = [(height/population median)^skewness - 1]/(skewness * population standard deviation) where skewness, median and standard deviation is given by a reference growth table for the corresponding chronological age. The range for HSDS was -10 to +10. Negative scores indicated a height below the mean height for a child with the same age and gender, whereas positive scores indicated a height above the mean height for a child with the same age and gender. Positive value in change from baseline in HSDS indicated that HSDS was better than baseline HSDS In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26
Change in Height Velocity Standard Deviation Score (HVSDS)
Délai: Baseline (week 0); week 26

Change in HVSDS from baseline (week 0) to week 26 is presented. HVSDS was derived using Prader standards. HV SDS was calculated using the formula: HV SDS = (height velocity - mean)/standard deviation (SD), where height velocity was the height velocity variable measured, mean and SD of height velocity by gender and age for the reference population. The range for HVSDS was -10 to +10. Negative scores indicated a height velocity below the mean height velocity for a child with the same age and gender, whereas positive scores indicated a height velocity above the mean height velocity for a child with the same age and gender. Positive value in change from baseline in HVSDS indicated that HVSDS was better than baseline HVSDS. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26
Change in Fasting Plasma Glucose
Délai: Baseline (week 0); week 26

Change in fasting plasma glucose from baseline (week 0) to week 26 is presented. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Homeostatic Model Assessment for Steady State Beta Cell Function (HOMA-B)
Délai: Baseline (week 0); week 26

Change in HOMA-B from baseline (week 0) to week 26 is presented. HOMA-B is a measure of the beta cell function and was calculated as follows: HOMA-B = (20 * fasting insulin (picomoles per liter [pmol/L]) * 1/6(microunit per milliliter [µU/mL]))/ FPG(mmol/L)-3.5). HOMA-beta score ranges from minus infinity to infinity (no limits). Higher score means better beta-cell function for HOMA-beta. Negative change from baseline (week 0) in HOMA-B indicated a worse outcome. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Délai: Baseline (week 0); week 26

Change in HOMA-IR from baseline (week 0) to week 26 is presented. Insulin resistance is a condition in which cells fail to respond to normal actions of hormone in body. HOMA-IR is calculated using a participant's fasting plasma insulin and glucose levels. HOMA-IR = fasting serum insulin (micro international units per milliliter (μU/ml)) × fasting plasma glucose (millimoles per liter (mmol/l)) / 22.5. HOMA-IR scores are classified as follows: less than 1.0: considered insulin sensitive, 0.5-1.4: considered healthy, above 1.8: considered early insulin resistance; above 2.7 is considered significant insulin resistance. HOMA-IR score ranges from 0-infinity (no upper limit). Higher the score, higher the level of insulin resistance. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Glycated Haemoglobin (HbA1c)
Délai: Baseline (week 0); week 26

Change in HbA1c from baseline (week 0) to week 26 is presented. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Insulin-like Growth Factor I (IGF-I) Standard Deviation Score (SDS)
Délai: Baseline (week 0); week 26

Change in IGF-I SDS from baseline (week 0) to week 26 is presented. IGF-I SDS was provided by the central laboratory; its calculation is based on the actual value of IGF-1 minus mean reference value of IGF-1 divided by reference standard deviation of IGF-1. The range for IGF-I SDS was from -10 to +10. Negative scores indicated a IGF-I below the mean IGF-I for a child with the same age and gender, whereas positive scores indicated a IGF-I above the mean IGF-I for a child with the same age and gender. Positive value in change from baseline in IGF-I SDS indicated that IGF-I SDS was higher than baseline IGF-I SDS. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) SDS
Délai: Baseline (week 0); week 26

Change in IGFBP-3 SDS from baseline (week 0) to week 26 is presented. The range for IGFBP-3 SDS was from -10 to +10. Negative scores indicated a IGFBP-3 below the mean IGFBP-3 for a child with the same age and gender, whereas positive scores indicated a IGFBP-3 above the mean IGFBP-3 for a child with the same age and gender. Positive value in change from baseline in IGFBP-3 SDS indicated that IGFBP-3 SDS was higher than baseline IGFBP-3 SDS. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Directeur d'études: Clinical Reporting Anchor and Disclosure 1452, Novo Nordisk A/S

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

4 juillet 2019

Achèvement primaire (Réel)

5 mai 2021

Achèvement de l'étude (Estimé)

23 décembre 2026

Dates d'inscription aux études

Première soumission

15 mars 2019

Première soumission répondant aux critères de contrôle qualité

15 mars 2019

Première publication (Réel)

18 mars 2019

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • NN8640-4245
  • 2018 (Subvention/contrat des NIH des États-Unis)
  • U1111-1207-9741 (Autre identifiant: World Health Organization (WHO))
  • 2018-000232-10 (Numéro EudraCT)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner